Therapy News and Research

RSS

Vertex presents data of telaprevir Phase 3b CONCISE study in people with genotype 1 chronic HCV

Vertex Pharmaceuticals Incorporated today announced new data from an interim analysis of the exploratory global Phase 3b CONCISE study evaluating the potential to shorten total treatment with telaprevir combination therapy to 12 weeks in certain people with genotype 1 chronic hepatitis C virus infection who have the IL28B CC genotype.

25 Apr 2013

Novel approach using Listeria bacteria shows promise against metastatic pancreatic cancer

Researchers at Albert Einstein College of Medicine of Yeshiva University have developed a therapy for pancreatic cancer that uses Listeria bacteria to selectively infect tumor cells and deliver radioisotopes into them.

25 Apr 2013

XBiotech announces enrollment of first patient in Xilonix Phase III trial for treatment of cachexia

XBiotech announced today enrollment of the first patient into its Phase III trial of Xilonix. The Pivotal study is designed to improve health and survival of late stage colorectal cancer patients with associated cachexia.

25 Apr 2013

FDA designates Merck's lambrolizumab as Breakthrough Therapy for advanced melanoma

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration has designated lambrolizumab (MK-3475) as a Breakthrough Therapy for the treatment of patients with advanced melanoma.

25 Apr 2013

Dietary substitution of saturated fats enriched in MCT prevents liver disease

Scientists at the Arkansas Children's Nutrition Center, a U.S. Department of Agriculture Agricultural Research Service Human Nutrition Research Center at the University of Arkansas for Medical Sciences, led by Dr. Martin Ronis have determined that dietary substitution of saturated fats enriched in medium chain triglycerides (MCT) for polyunsaturated fat prevents the development of nonalcoholic fatty liver disease (NAFLD).

25 Apr 2013

American Heart Association: Direct, indirect costs to treat heart failure could more than double in 2030

By 2030, you - and every U.S. taxpayer - could be paying $244 a year to care for heart failure patients, according to an American Heart Association policy statement.

25 Apr 2013

Sofosbuvir is safer than interferon for hepatitis C patients, say scientists

A new drug is offering dramatic cure rates for hepatitis C patients with two subtypes of the infection -- genotype 2 and 3, say a team of scientists led by Weill Cornell Medical College researchers.

25 Apr 2013

Individuals with MEN1 are at increased risk of developing neuroendocrine tumors

A mutation in a protein called menin causes a hereditary cancer syndrome called MEN1 (multiple endocrine neoplasia type 1).

25 Apr 2013

Hospital for Special Surgery receives grant for new genomics center to study autoimmune diseases

Hospital for Special Surgery in New York City has received a $5.6 million grant from The Tow Foundation to establish the Hospital for Special Surgery Genomics Center.

25 Apr 2013

Study reveals 3-D motion detection system could help prevent shoulder injuries in baseball pitchers

A new 3-D motion detection system could help identify baseball pitchers who are at risk for shoulder injuries, according to a new study.

24 Apr 2013

Promising development for women with triple-negative breast cancer

Tamoxifen is a time-honored breast cancer drug used to treat millions of women with early-stage and less-aggressive disease, and now a University of Rochester Medical Center team has shown how to exploit tamoxifen's secondary activities so that it might work on more aggressive breast cancer.

24 Apr 2013

Tissue engineering combined with gene therapy can manage repair of defective articular cartilage

Researchers at Micro Orthopaedics, Zhongnan Hospital of Wuhan University, led by Dr. Ai-xi Yu, have suggested that articular cartilage defects can be repaired by a novel thermo-sensitive injectable hydrogel engineered with gene modified bone marrow mesenchymal stromal cells.

24 Apr 2013

Phase IIb Aviator study demonstrates high SVR rates against genotype 1 HCV

Results from "Aviator," AbbVie's phase IIb clinical trial of its investigational direct-acting antivirals for the treatment of hepatitis C virus infection, continue to demonstrate high sustained viral response rates against genotype 1 HCV, across patient types.

24 Apr 2013

Research project to identify mechanisms underlying effects of cancer drug interferon-α

The immune system plays a decisive role in the fight against tumor cells. However, when tumor cells themselves prevent activation of the immune system, the immune system fails to destroy cancer cells.

24 Apr 2013

CytRx reaches agreement with FDA for aldoxorubicin Phase 3 trial for treatment of soft tissue sarcomas

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, announced today that it has reached an agreement with the U.S. Food and Drug Administration under a special protocol assessment for a global pivotal Phase 3 trial with aldoxorubicin as a treatment for patients with soft tissue sarcomas who have relapsed or were refractory following prior treatment with chemotherapy.

24 Apr 2013

Research: DBS may provide therapeutic relief to binge eating

Deep brain stimulation in a precise region of the brain appears to reduce caloric intake and prompt weight loss in obese animal models, according to a new study led by researchers at the University of Pennsylvania.

24 Apr 2013

Methodist Hospital will soon have new brain and pituitary tumor treatment center

Brain and pituitary tumor patients will soon have access to a state-of-the-art facility at The Methodist Hospital, a result of a $10 million dollar commitment from a Houston oil executive.

24 Apr 2013

Investigational treatment for ALS passes early phase clinical trial for safety

An investigational treatment for an inherited form of Lou Gehrig's disease has passed an early phase clinical trial for safety, researchers at Washington University School of Medicine in St. Louis and Massachusetts General Hospital report.

24 Apr 2013

FDA grants orphan-drug designation to XEN402 for treatment of pain associated with EM

Teva Pharmaceutical Industries Ltd. and Xenon Pharmaceuticals Inc. announced today that the US Food and Drug Administration has granted orphan-drug designation to the investigational drug XEN402 being developed for the treatment of pain associated with erythromelalgia.

24 Apr 2013

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of the latest interim data from a Phase II, multi-center, randomized, dose-ranging clinical trial evaluating the safety and antiviral activity of MK-5172, for the treatment of chronic hepatitis C virus genotype 1 infection.

24 Apr 2013

Therapy News and Research

Vertex presents data of telaprevir Phase 3b CONCISE study in people with genotype 1 chronic HCV

Novel approach using Listeria bacteria shows promise against metastatic pancreatic cancer

XBiotech announces enrollment of first patient in Xilonix Phase III trial for treatment of cachexia

FDA designates Merck's lambrolizumab as Breakthrough Therapy for advanced melanoma

Dietary substitution of saturated fats enriched in MCT prevents liver disease

American Heart Association: Direct, indirect costs to treat heart failure could more than double in 2030

Sofosbuvir is safer than interferon for hepatitis C patients, say scientists

Individuals with MEN1 are at increased risk of developing neuroendocrine tumors

Hospital for Special Surgery receives grant for new genomics center to study autoimmune diseases

Study reveals 3-D motion detection system could help prevent shoulder injuries in baseball pitchers

Promising development for women with triple-negative breast cancer

Tissue engineering combined with gene therapy can manage repair of defective articular cartilage

Phase IIb Aviator study demonstrates high SVR rates against genotype 1 HCV

Research project to identify mechanisms underlying effects of cancer drug interferon-α

CytRx reaches agreement with FDA for aldoxorubicin Phase 3 trial for treatment of soft tissue sarcomas

Research: DBS may provide therapeutic relief to binge eating

Methodist Hospital will soon have new brain and pituitary tumor treatment center

Investigational treatment for ALS passes early phase clinical trial for safety

FDA grants orphan-drug designation to XEN402 for treatment of pain associated with EM

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

Industry Focus eBook - Cell biology (5th edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News